Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 148 | 2024 | 5387 | 12.420 |
Why?
|
Receptor Protein-Tyrosine Kinases | 68 | 2023 | 1621 | 10.600 |
Why?
|
Lung Neoplasms | 182 | 2024 | 13485 | 10.550 |
Why?
|
Protein Kinase Inhibitors | 102 | 2024 | 5690 | 7.790 |
Why?
|
Pyrazoles | 72 | 2024 | 2030 | 7.340 |
Why?
|
Lactams, Macrocyclic | 28 | 2024 | 319 | 6.870 |
Why?
|
Carbazoles | 19 | 2024 | 230 | 5.590 |
Why?
|
Protein-Tyrosine Kinases | 33 | 2023 | 2426 | 5.450 |
Why?
|
Pyridines | 52 | 2024 | 2888 | 5.420 |
Why?
|
Gene Rearrangement | 29 | 2024 | 1142 | 4.150 |
Why?
|
Drug Resistance, Neoplasm | 50 | 2024 | 5329 | 4.140 |
Why?
|
Proto-Oncogene Proteins | 31 | 2021 | 4522 | 4.120 |
Why?
|
Sulfones | 17 | 2021 | 447 | 3.510 |
Why?
|
Piperidines | 20 | 2024 | 1663 | 3.500 |
Why?
|
Lactams | 23 | 2024 | 159 | 2.790 |
Why?
|
Antineoplastic Agents | 50 | 2024 | 13643 | 2.690 |
Why?
|
Aminopyridines | 24 | 2024 | 577 | 2.280 |
Why?
|
Oncogene Proteins, Fusion | 19 | 2021 | 1609 | 2.250 |
Why?
|
Pyrimidines | 24 | 2021 | 3043 | 2.150 |
Why?
|
Mutation | 59 | 2024 | 30213 | 1.340 |
Why?
|
Brain Neoplasms | 18 | 2022 | 9101 | 1.330 |
Why?
|
Proto-Oncogene Proteins c-ret | 5 | 2018 | 228 | 1.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2024 | 11872 | 1.050 |
Why?
|
Translocation, Genetic | 6 | 2016 | 1392 | 0.900 |
Why?
|
Indazoles | 5 | 2019 | 306 | 0.890 |
Why?
|
Azetidines | 1 | 2024 | 151 | 0.850 |
Why?
|
Taxoids | 6 | 2017 | 665 | 0.830 |
Why?
|
Adenocarcinoma | 12 | 2018 | 6359 | 0.810 |
Why?
|
ras Proteins | 7 | 2015 | 1055 | 0.810 |
Why?
|
Humans | 204 | 2024 | 766766 | 0.750 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 1762 | 0.730 |
Why?
|
Benzamides | 6 | 2021 | 1375 | 0.710 |
Why?
|
Genes, erbB-1 | 2 | 2017 | 161 | 0.610 |
Why?
|
Platinum | 1 | 2019 | 219 | 0.600 |
Why?
|
Receptor, trkA | 4 | 2020 | 159 | 0.580 |
Why?
|
Molecular Targeted Therapy | 16 | 2023 | 2823 | 0.580 |
Why?
|
In Situ Hybridization, Fluorescence | 11 | 2020 | 2510 | 0.570 |
Why?
|
Genetic Heterogeneity | 3 | 2017 | 735 | 0.570 |
Why?
|
Drug Resistance | 2 | 2013 | 1592 | 0.560 |
Why?
|
Middle Aged | 87 | 2024 | 223257 | 0.560 |
Why?
|
Prognosis | 27 | 2022 | 29948 | 0.550 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2019 | 2056 | 0.550 |
Why?
|
Aged | 75 | 2024 | 171343 | 0.540 |
Why?
|
Adult | 79 | 2024 | 223307 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-met | 7 | 2021 | 562 | 0.490 |
Why?
|
Organophosphorus Compounds | 4 | 2018 | 209 | 0.490 |
Why?
|
Female | 103 | 2024 | 396520 | 0.490 |
Why?
|
Anilides | 3 | 2022 | 413 | 0.480 |
Why?
|
Neoplasms | 12 | 2020 | 22350 | 0.470 |
Why?
|
Genomic Instability | 2 | 2023 | 716 | 0.470 |
Why?
|
Maximum Tolerated Dose | 5 | 2024 | 895 | 0.470 |
Why?
|
Guanine | 2 | 2013 | 280 | 0.470 |
Why?
|
Glutamates | 2 | 2013 | 384 | 0.460 |
Why?
|
Male | 95 | 2024 | 364142 | 0.460 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 260 | 0.450 |
Why?
|
Puerperal Disorders | 1 | 2016 | 304 | 0.430 |
Why?
|
Meningeal Carcinomatosis | 1 | 2013 | 65 | 0.430 |
Why?
|
Disease-Free Survival | 12 | 2017 | 6850 | 0.410 |
Why?
|
Clinical Trials, Phase I as Topic | 5 | 2019 | 329 | 0.410 |
Why?
|
HSP90 Heat-Shock Proteins | 4 | 2018 | 422 | 0.400 |
Why?
|
Aged, 80 and over | 40 | 2021 | 59550 | 0.400 |
Why?
|
Cell Line, Tumor | 20 | 2021 | 17088 | 0.380 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2561 | 0.360 |
Why?
|
Genes, ras | 4 | 2009 | 656 | 0.350 |
Why?
|
Immunotherapy | 7 | 2018 | 4747 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 10745 | 0.340 |
Why?
|
Survival Rate | 9 | 2019 | 12825 | 0.320 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 488 | 0.320 |
Why?
|
Treatment Outcome | 28 | 2024 | 65273 | 0.320 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 1168 | 0.310 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 926 | 0.310 |
Why?
|
Loss of Heterozygosity | 1 | 2010 | 663 | 0.300 |
Why?
|
Acrylamides | 4 | 2018 | 260 | 0.300 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2019 | 454 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 11 | 2018 | 6512 | 0.290 |
Why?
|
Young Adult | 26 | 2021 | 59939 | 0.280 |
Why?
|
Spinal Neoplasms | 1 | 2013 | 714 | 0.280 |
Why?
|
Tumor Burden | 5 | 2020 | 1900 | 0.280 |
Why?
|
Gene Fusion | 2 | 2019 | 356 | 0.270 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 8621 | 0.270 |
Why?
|
Hypogonadism | 1 | 2012 | 802 | 0.250 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 903 | 0.250 |
Why?
|
Clinical Trials as Topic | 9 | 2020 | 8045 | 0.250 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1255 | 0.250 |
Why?
|
Retrospective Studies | 26 | 2022 | 81635 | 0.250 |
Why?
|
Survival Analysis | 6 | 2020 | 10100 | 0.250 |
Why?
|
Quinazolines | 4 | 2018 | 1367 | 0.250 |
Why?
|
Biopsy | 8 | 2021 | 6779 | 0.250 |
Why?
|
Neoplasm Staging | 12 | 2020 | 11218 | 0.240 |
Why?
|
Patient Selection | 4 | 2020 | 4252 | 0.240 |
Why?
|
DNA Mutational Analysis | 7 | 2019 | 4114 | 0.240 |
Why?
|
Aspartate Aminotransferases | 2 | 2017 | 416 | 0.240 |
Why?
|
Retreatment | 2 | 2017 | 598 | 0.240 |
Why?
|
Gene Amplification | 3 | 2020 | 1088 | 0.240 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39309 | 0.230 |
Why?
|
Immunohistochemistry | 6 | 2020 | 11061 | 0.230 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 168 | 0.230 |
Why?
|
Drug Delivery Systems | 2 | 2013 | 2210 | 0.230 |
Why?
|
Neoplasm Metastasis | 6 | 2022 | 4891 | 0.230 |
Why?
|
Intention to Treat Analysis | 3 | 2020 | 418 | 0.230 |
Why?
|
Receptor, trkB | 3 | 2019 | 123 | 0.230 |
Why?
|
Alanine Transaminase | 2 | 2017 | 608 | 0.220 |
Why?
|
Genotype | 8 | 2017 | 13036 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 10 | 2019 | 20708 | 0.200 |
Why?
|
Disease Progression | 10 | 2020 | 13640 | 0.200 |
Why?
|
Animals | 26 | 2024 | 168930 | 0.190 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 249 | 0.190 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2430 | 0.190 |
Why?
|
Testosterone | 1 | 2012 | 2495 | 0.180 |
Why?
|
Lung | 5 | 2019 | 10067 | 0.180 |
Why?
|
Food-Drug Interactions | 1 | 2020 | 26 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3607 | 0.170 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4853 | 0.170 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 268 | 0.170 |
Why?
|
Oxidative Stress | 1 | 2011 | 3139 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3666 | 0.170 |
Why?
|
Mice | 18 | 2024 | 81889 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 71 | 0.160 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2017 | 718 | 0.160 |
Why?
|
Radiosurgery | 3 | 2018 | 1329 | 0.160 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 199 | 0.160 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.150 |
Why?
|
Pyridazines | 1 | 2020 | 199 | 0.150 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 50 | 0.150 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1742 | 0.150 |
Why?
|
Aniline Compounds | 3 | 2018 | 1079 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 114 | 0.150 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 330 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2018 | 8540 | 0.150 |
Why?
|
Imidazoles | 2 | 2021 | 1168 | 0.140 |
Why?
|
Drug Discovery | 2 | 2016 | 1065 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 224 | 0.140 |
Why?
|
gamma-Glutamyltransferase | 1 | 2017 | 142 | 0.140 |
Why?
|
Isoxazoles | 1 | 2018 | 233 | 0.140 |
Why?
|
Platinum Compounds | 1 | 2017 | 94 | 0.140 |
Why?
|
Oncogene Fusion | 1 | 2017 | 84 | 0.140 |
Why?
|
Transcription Factors | 2 | 2020 | 12150 | 0.140 |
Why?
|
Disease Models, Animal | 6 | 2019 | 18330 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4570 | 0.130 |
Why?
|
Bone Morphogenetic Protein 3 | 1 | 2016 | 17 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9404 | 0.130 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 161 | 0.130 |
Why?
|
Genomics | 5 | 2023 | 5923 | 0.130 |
Why?
|
Gene Order | 1 | 2016 | 165 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2020 | 421 | 0.130 |
Why?
|
Protein Conformation | 2 | 2014 | 3947 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 904 | 0.130 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 663 | 0.130 |
Why?
|
DNA, Neoplasm | 2 | 2018 | 1741 | 0.130 |
Why?
|
Mice, Nude | 4 | 2020 | 3616 | 0.130 |
Why?
|
Hyperlipidemias | 1 | 2020 | 771 | 0.130 |
Why?
|
Endpoint Determination | 2 | 2016 | 592 | 0.120 |
Why?
|
Peripartum Period | 1 | 2016 | 137 | 0.120 |
Why?
|
DNA Helicases | 1 | 2020 | 853 | 0.120 |
Why?
|
Thoracic Neoplasms | 1 | 2017 | 269 | 0.120 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 406 | 0.120 |
Why?
|
Family Characteristics | 1 | 2019 | 1002 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 348 | 0.120 |
Why?
|
Quality of Life | 6 | 2022 | 13476 | 0.110 |
Why?
|
Scleroderma, Localized | 1 | 2015 | 85 | 0.110 |
Why?
|
Cohort Studies | 6 | 2019 | 41710 | 0.110 |
Why?
|
Membrane Glycoproteins | 3 | 2019 | 3702 | 0.110 |
Why?
|
Exons | 2 | 2018 | 2392 | 0.110 |
Why?
|
Benzoquinones | 1 | 2014 | 198 | 0.110 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 803 | 0.110 |
Why?
|
Creatine Kinase | 1 | 2015 | 683 | 0.110 |
Why?
|
Arthritis, Experimental | 1 | 2016 | 293 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 464 | 0.110 |
Why?
|
Liver Failure | 1 | 2015 | 252 | 0.110 |
Why?
|
Kidney Diseases, Cystic | 1 | 2015 | 182 | 0.110 |
Why?
|
Time Factors | 5 | 2019 | 40149 | 0.110 |
Why?
|
Codon | 1 | 2015 | 599 | 0.110 |
Why?
|
Structure-Activity Relationship | 2 | 2021 | 3053 | 0.100 |
Why?
|
Gene Deletion | 1 | 2020 | 2669 | 0.100 |
Why?
|
Thymidylate Synthase | 1 | 2012 | 74 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2019 | 638 | 0.100 |
Why?
|
Administration, Oral | 3 | 2017 | 4018 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2017 | 10445 | 0.100 |
Why?
|
Piperazines | 3 | 2019 | 2547 | 0.100 |
Why?
|
Language | 1 | 2021 | 1550 | 0.100 |
Why?
|
Internationality | 1 | 2017 | 1006 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6895 | 0.100 |
Why?
|
Edema | 1 | 2015 | 764 | 0.100 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 161 | 0.090 |
Why?
|
Oncogenes | 2 | 2016 | 1231 | 0.090 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1733 | 0.090 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 2631 | 0.090 |
Why?
|
Enzyme Inhibitors | 3 | 2017 | 3721 | 0.090 |
Why?
|
Molecular Structure | 1 | 2015 | 1882 | 0.090 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 755 | 0.090 |
Why?
|
Immunoblotting | 2 | 2012 | 1647 | 0.090 |
Why?
|
Benzimidazoles | 2 | 2015 | 862 | 0.090 |
Why?
|
Enzyme Activation | 2 | 2014 | 3587 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1802 | 0.090 |
Why?
|
Constipation | 1 | 2015 | 568 | 0.090 |
Why?
|
Protein Stability | 1 | 2012 | 578 | 0.090 |
Why?
|
Osteoblasts | 1 | 2016 | 1144 | 0.090 |
Why?
|
Cell Survival | 2 | 2019 | 5748 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2021 | 3511 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7868 | 0.080 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2011 | 614 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 543 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6307 | 0.080 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 3531 | 0.080 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1028 | 0.080 |
Why?
|
Recombination, Genetic | 1 | 2014 | 1525 | 0.080 |
Why?
|
Models, Molecular | 2 | 2021 | 5386 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1042 | 0.080 |
Why?
|
Prospective Studies | 6 | 2019 | 54871 | 0.080 |
Why?
|
Receptor, trkC | 2 | 2019 | 63 | 0.080 |
Why?
|
Cell Lineage | 1 | 2017 | 2572 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2533 | 0.080 |
Why?
|
Fatigue | 1 | 2015 | 1555 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1838 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2012 | 427 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2018 | 4049 | 0.080 |
Why?
|
Melanoma | 2 | 2017 | 5700 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2456 | 0.070 |
Why?
|
Microfluidics | 1 | 2013 | 650 | 0.070 |
Why?
|
Australia | 1 | 2011 | 1263 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 878 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 902 | 0.070 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 2 | 2021 | 318 | 0.070 |
Why?
|
Cell Separation | 1 | 2013 | 1718 | 0.070 |
Why?
|
Fibroblasts | 2 | 2011 | 4166 | 0.070 |
Why?
|
Environment | 1 | 2013 | 1120 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2603 | 0.070 |
Why?
|
Embryo Loss | 1 | 2007 | 55 | 0.070 |
Why?
|
Vision Disorders | 1 | 2014 | 1090 | 0.070 |
Why?
|
Binding Sites | 1 | 2015 | 6012 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1882 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8507 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 3425 | 0.070 |
Why?
|
DNA Primers | 1 | 2011 | 2826 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 949 | 0.070 |
Why?
|
Adolescent | 6 | 2019 | 88904 | 0.070 |
Why?
|
Thrombosis | 1 | 2020 | 2953 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1331 | 0.060 |
Why?
|
Mice, SCID | 3 | 2018 | 2628 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6104 | 0.060 |
Why?
|
Cell Death | 1 | 2011 | 1676 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5795 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1540 | 0.060 |
Why?
|
Deglutition Disorders | 1 | 2011 | 640 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1998 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2057 | 0.060 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2007 | 3609 | 0.060 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1442 | 0.060 |
Why?
|
Signal Transduction | 5 | 2021 | 23619 | 0.050 |
Why?
|
Cranial Irradiation | 2 | 2018 | 392 | 0.050 |
Why?
|
Uridine | 1 | 2023 | 135 | 0.050 |
Why?
|
Risk Assessment | 2 | 2017 | 24295 | 0.050 |
Why?
|
Glucuronosyltransferase | 1 | 2023 | 136 | 0.050 |
Why?
|
Transfection | 1 | 2011 | 5754 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2011 | 2142 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 513 | 0.050 |
Why?
|
Self Report | 1 | 2014 | 3771 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8926 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2948 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2009 | 1885 | 0.050 |
Why?
|
Risk Factors | 4 | 2020 | 74881 | 0.050 |
Why?
|
Smoking | 1 | 2019 | 9077 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2016 | 12791 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15908 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10384 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2011 | 5890 | 0.040 |
Why?
|
Apoptosis | 2 | 2019 | 9513 | 0.040 |
Why?
|
Pregnancy | 2 | 2016 | 30237 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2024 | 1057 | 0.040 |
Why?
|
Phosphorylation | 1 | 2011 | 8307 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2007 | 1491 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3944 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4353 | 0.040 |
Why?
|
Receptors, Growth Factor | 2 | 2010 | 324 | 0.040 |
Why?
|
Genetic Engineering | 1 | 2005 | 936 | 0.040 |
Why?
|
Congenital Abnormalities | 1 | 2004 | 703 | 0.040 |
Why?
|
Drug Interactions | 1 | 2023 | 1419 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 311 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 605 | 0.040 |
Why?
|
Genetic Testing | 1 | 2011 | 3591 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12985 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 37 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2020 | 874 | 0.040 |
Why?
|
INDEL Mutation | 1 | 2018 | 266 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5861 | 0.040 |
Why?
|
Neurofibromin 1 | 1 | 2018 | 190 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2007 | 9547 | 0.030 |
Why?
|
RNA | 1 | 2007 | 2715 | 0.030 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2020 | 382 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6962 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12534 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2885 | 0.030 |
Why?
|
Phthalazines | 1 | 2019 | 397 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2007 | 2902 | 0.030 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2016 | 83 | 0.030 |
Why?
|
Base Sequence | 1 | 2007 | 12415 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 18984 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10619 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 615 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15416 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2020 | 723 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 2020 | 3439 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9461 | 0.030 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 147 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2801 | 0.030 |
Why?
|
Quinazolinones | 1 | 2016 | 219 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2839 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 107 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 655 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 1996 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1838 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2470 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2198 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 203 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1627 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1325 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18397 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4142 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2039 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 22352 | 0.020 |
Why?
|
Albumins | 1 | 2015 | 578 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 938 | 0.020 |
Why?
|
Cell Shape | 1 | 2013 | 372 | 0.020 |
Why?
|
Carboplatin | 1 | 2015 | 789 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2007 | 14471 | 0.020 |
Why?
|
Skull | 1 | 2016 | 819 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1604 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2018 | 1147 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 625 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1574 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21525 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 747 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1105 | 0.020 |
Why?
|
Western World | 1 | 2009 | 26 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2045 | 0.020 |
Why?
|
Mass Screening | 1 | 2005 | 5454 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2015 | 1320 | 0.020 |
Why?
|
Drug Approval | 1 | 2016 | 820 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5022 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2275 | 0.020 |
Why?
|
United States | 2 | 2018 | 72951 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9244 | 0.020 |
Why?
|
Paclitaxel | 1 | 2015 | 1727 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3564 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2901 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10264 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8891 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 789 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1027 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1071 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7585 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4349 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4855 | 0.010 |
Why?
|
Genetics, Population | 1 | 2009 | 943 | 0.010 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2004 | 84 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8728 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 2004 | 752 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6066 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 711 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2005 | 1751 | 0.010 |
Why?
|
Integrases | 1 | 2004 | 520 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 705 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6207 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1787 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4215 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 36567 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2004 | 1675 | 0.010 |
Why?
|
Viral Proteins | 1 | 2004 | 1801 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2005 | 1351 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 3552 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4474 | 0.010 |
Why?
|
Cell Cycle | 1 | 2004 | 2926 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2010 | 6550 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16724 | 0.010 |
Why?
|
Brain | 1 | 2018 | 27159 | 0.010 |
Why?
|
Stem Cells | 1 | 2004 | 3537 | 0.010 |
Why?
|
Child | 1 | 2018 | 80668 | 0.010 |
Why?
|